Rosetta Genomics (ROSG) Says Medicare Admin to Cover miRview Mets Assay
Tweet
Share
E-mailGet Alerts ROSG Hot Sheet
Join SI Premium – FREE
Rosetta Genomics Ltd. (Nasdaq: ROSG), announced that Novitas, the designated Medicare Administrative Contractor for the Company's miRview mets assay, has informed Rosetta that it plans to cover this assay for all Medicare beneficiaries.
MiRview mets accurately identifies the primary tumor of origin in primary and metastatic cancer including Cancer of Unknown or Uncertain Primary.
MiRview mets accurately identifies the primary tumor of origin in primary and metastatic cancer including Cancer of Unknown or Uncertain Primary.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Sky Quarry names Heidi Bowman as CFO
- Walmart opens its 100th EV fast-charging site in Monument, CO
- Solana Company announces votes on first Solana governance proposals
Create E-mail Alert Related Categories
Corporate News, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
